Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 19/20 | 0.47 |
| ▸ | FNTB | P49356 | 19/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 17/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7220637 | 0.99 | FNTA (0.47) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL7672909 | 0.85 | CYP17A1 (0.48) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL7228262 | 0.84 | CYP11B1 (0.40) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL7673750 | 0.83 | FNTA (0.44) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL7566587 | 0.80 | FNTB (0.42) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL7677921 | 0.80 | CYP11B1 (0.39) | FNTAFNTBCYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL7220477 | 0.78 | FNTA (0.38) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL7220321 | 0.76 | FNTA (0.41) | FNTAFNTBPGGT1B | |
| SCHEMBL7736904 | 0.75 | S1PR3 (0.42) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL7970458 | 0.75 | FNTA (0.60) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6566385-B2 | And the prenylation of the oncogene protein Ras; peptidomimetic macrocyclic compounds | MERCK & CO., INC. | 2003-05-20 | — | — | US | disclosed |
| US-6525074-B2 | Peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras | MERCK & CO., INC. | 2003-02-25 | — | — | US | disclosed |
| US-20020099007-A1 | Inhibitors of prenyl-protein transferase | MERCK SHARP & DOHME CORP. | 2002-07-25 | — | — | US | disclosed |
| US-6413964-B1 | 14-AMINO-14-(1-METHYL-1H-IMIDAZOL-5-YL)-8-OXA-2-THIA-1,18 -DIAZATETRACYCLO(16.2.2.1(3,7).1(9,13))TETRACOSA-3(24),4,6, 9(23),10,12-HEXAENE-10-CARBONITRILE 2,2-DIOXIDE, FOR EXAMPLE; USE IN RADIOTHERAPY, CHEMOTHERAPY AS SENSITIZER | MERCK & CO., INC. | 2002-07-02 | — | — | US | disclosed |
| US-20020049217-A1 | Inhibitors of prenyl-protein transferase | MERCK SHARP & DOHME CORP. | 2002-04-25 | — | — | US | disclosed |
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | MERCK & CO., INC. | 2002-03-28 | — | — | US | disclosed |
| US-6284755-B1 | Inhibitors of prenyl-protein transferase | MERCK & CO., INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2001051125-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001051126-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2000034247-A2 | METHOD FOR PRODUCING PYRAZOLYLBENZOYL DERIVATIVES AND NOVEL PYRAZOLYLBENZOYL DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034437-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049217-A1 | Inhibitors of prenyl-protein transferase | FNTA, KRAS, NRAS | FNTA 1/4885FNTB 5/4885PGGT1B 122/4885 |
| US-20020099007-A1 | Inhibitors of prenyl-protein transferase | FNTA, KRAS, NRAS | FNTA 1/4885FNTB 5/4885PGGT1B 122/4885 |
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | FNTA, PKD1, FNTB | FNTA 1/4885FNTB 3/4885PGGT1B 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.